Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)
NCT00246909
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
600
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophageal Reflux
Interventions
DRUG:
Pantoprazole
Sponsor
Takeda